Bishop Michael F. Burbidge of Arlington, chairman of the U.S. Conference of Catholic Bishops’ Committee on Pro-Life Activities, provided a statement in response to the U.S. Court of Appeals for the Fifth Circuit partially upholding a recent district court ruling to reverse preliminarily the U.S. Food and Drug Administration’s loosening of access and safety standards for the abortion drug, mifepristone.
Click "Read More" to view the statement.